This Week in Peptide Research: Orforglipron's Phase 3 Data From Japan, and a Reality Check on BPC-157 and TB-500

Peptide Science Daily reviewed new PubMed listings for its tracked compounds from October 26 through November 1, 2026. The week's lead story was new regional phase 3 data for an already-approved weight-loss drug, followed by two papers probing the durability of a combination therapy still awaiting its first approval, a comparative-effectiveness study of GLP-1 drugs in a difficult-to-treat kidney population, a pediatric safety case tied to a long-approved short bowel syndrome drug, and a surgical specialty review that pushed back on two widely marketed research peptides.

The Lancet Diabetes & Endocrinology published results from ATTAIN-J, a phase 3 trial testing once-daily oral orforglipron in 238 Japanese adults with obesity, registered as NCT05931380 and sponsored by Eli Lilly. Participants were randomly assigned to 6 mg, 12 mg, or 36 mg of orforglipron or placebo for 72 weeks; 90 percent completed the trial. Mean weight loss was 5.9, 8.7, and 7.9 percent across the three doses, compared with 0.6 percent with placebo, and 46 to 61 percent of participants on orforglipron lost at least 5 percent of their body weight versus 15 percent on placebo. Adverse events were mostly mild-to-moderate gastrointestinal symptoms, with nausea and vomiting the most common reasons participants stopped treatment; the authors described the safety profile as consistent with other GLP-1 receptor agonists. Orforglipron was approved by the FDA as Foundayo in April 2026 for chronic weight management in adults with obesity or overweight with weight-related conditions, based on its US and European ATTAIN trials; it is not yet approved for type 2 diabetes and has no EMA or TGA authorization. The ATTAIN-J results extend that approved obesity indication's evidence base to a Japanese population rather than establishing a new use.

Two papers this week examined CagriSema, Novo Nordisk's fixed-dose combination of the amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide, from different angles. In Diabetes, Obesity and Metabolism, researchers from IMU University and Monash University Malaysia published a dose- and comparator-specific Bayesian meta-analysis of six randomized trials covering 4,554 participants with type 2 diabetes. Against placebo, CagriSema 2.4 mg lowered HbA1c by 1.87 percentage points and body weight by 12.69 percentage points; against semaglutide 2.4 mg alone, the additional HbA1c reduction was modest and statistically uncertain, while the additional weight-loss benefit, 5.84 percentage points, was considered probable. Gastrointestinal adverse events and treatment discontinuations were roughly two to three times more common than with placebo. Separately, in Molecular Metabolism, a Novo Nordisk-affiliated research team reported a mechanistic study in diet-induced obese rats, tracking energy intake and expenditure through six weeks of CagriSema treatment, four weeks of weight maintenance, and ten days after stopping the drug. Reduced food intake accounted for 86 percent of the weight-loss effect and preserved energy expenditure for the remaining 14 percent; once treatment stopped, rats became hyperphagic and regained weight rapidly, with the metabolic effects reversing within about a week, leading the authors to conclude that sustained weight loss may require continued treatment. Semaglutide is FDA-approved for type 2 diabetes and, as Wegovy, for weight management; cagrilintide remains investigational, with a CagriSema new drug application filed with the FDA and a decision expected later in 2026.

In Diabetes Care, researchers from Thomas Jefferson University, Johns Hopkins, and New York University published a target-trial emulation using 2011 to 2022 US Renal Data System and Medicare records to compare semaglutide against dulaglutide or liraglutide in 3,200 effective patients with diabetes on maintenance hemodialysis. After adjusting for confounders, semaglutide was associated with lower one-year mortality on dialysis (11 percent versus 13 percent) and lower all-cause hospitalization (57 percent versus 62 percent) than dulaglutide or liraglutide combined, along with greater one-year weight loss (4.8 percent versus 3.4 percent). The mortality and hospitalization benefit held in a direct comparison against dulaglutide alone but was not statistically significant against liraglutide alone. The authors concluded that, when clinicians are choosing between these GLP-1 drugs for dialysis patients, semaglutide may be the preferred option over dulaglutide. All three drugs are FDA-approved for type 2 diabetes; the study describes comparative outcomes in an already-approved use in a specific patient population rather than a new approval.

A case report in JPGN Reports from Boston Children's Hospital described a pediatric patient treated with teduglutide for five years for intestinal failure who developed diffuse proliferation of the gallbladder's lining, found incidentally, with persistently normal liver and bile-duct blood tests and no gallstones. Teduglutide, a GLP-2 analog that promotes growth of the intestinal lining, was FDA-approved as Gattex for adults with short bowel syndrome in 2012 and later extended to pediatric patients. The authors wrote that the finding may warrant additional monitoring during long-term use of the drug, which already carries manufacturer warnings about gastrointestinal tract growths; they did not report evidence of cancer or a need to discontinue the drug in this patient.

Away from the GLP-1 field, the Journal of the American Academy of Orthopaedic Surgeons published a review from NYU Langone Health and Baptist Health South Florida on BPC-157, thymosin beta-4, and the thymosin beta-4 fragment sold as TB-500, all marketed for musculoskeletal recovery despite limited clinical validation. The authors, searching the literature through June 2026 alongside primary regulatory and anti-doping sources, reported that BPC-157 has the largest body of preclinical tendon, ligament, muscle, and bone evidence, almost entirely in small animals, with human musculoskeletal evidence limited to one small, uncontrolled retrospective case series without validated outcome measures. Thymosin beta-4 has broader human experience in eye, skin, and heart research but little direct musculoskeletal data, and TB-500 is a distinct seven-amino-acid fragment that the review said is frequently and incorrectly treated as equivalent to full-length thymosin beta-4. The authors noted product quality concerns with commercially sold peptides, including identity, purity, and sterility, and concluded that none of the three has an FDA-approved musculoskeletal indication or controlled human orthopaedic efficacy data, advising that routine clinical use cannot currently be recommended and that surgeons should ask patients about peptide use and counsel on anti-doping restrictions. BPC-157 is a Schedule 4 prescription-only substance in Australia and is barred from compounding in the United States; TB-500 is prohibited in sport by WADA at all times. Neither is approved as a medicine anywhere.

This week's coverage ran from new regional trial data for an approved obesity drug to durability and comparative-effectiveness questions around GLP-1 therapies, a long-term safety signal in an established short bowel syndrome drug, and a specialty-society review urging caution on two unregulated research peptides. Orforglipron, semaglutide, dulaglutide, liraglutide, and teduglutide are each approved for at least one indication in at least one jurisdiction; cagrilintide remains investigational with no approval anywhere; BPC-157 is restricted and TB-500 is prohibited in sport, with neither approved as a medicine anywhere. As with all research covered here, these are findings each study or review reported, not established clinical fact or treatment guidance.